论文部分内容阅读
目的 :观察奥美拉唑、阿莫西林、呋喃唑酮短程三联疗法作为二线方案根除幽门螺杆菌 (Helicobacterpylori,HP)的疗效和安全性。方法 :16 3例经以质子泵抑制剂为基础的三联疗法根除失败或根除后复发的HP感染病人 ,随机分为A、B、C 3组 ,A组 (n =5 5 ,男性 42 ,女性 13,年龄 6 3± 13岁 )予以奥美拉唑 (O) 2 0mg、阿莫西林 (A) 10 0 0mg、呋喃唑酮 (F) 10 0mg ,bid ,疗程 7d(简称OAF方案 ) ;B组 (n =5 4,男性 44,女性 10 ,年龄 6 1± 13岁 )予以奥美拉唑 2 0mg、德诺(C) 2 40mg、甲硝唑 (M ) 40 0mg ,bid ,四环素 (T) 5 0 0mg ,qid ,疗程 7d(简称OCMT方案 ) ;C组 (n =5 4男性 43,女性 11,年龄 6 2± 17)予以奥美拉唑 2 0mg、德诺 2 40mg、甲硝唑 40 0mg、阿莫西林 10 0 0mg ,bid ,疗程 7d(简称OCMA方案 )。抗HP治疗结束 1月后 ,全部做13 C 尿素呼气试验。结果 :3组各失访 1例 ,B组因药物不良反应 (ADR)退出 2例 ,C组因ADR退出 1例。A、B、C 3组的HP根除率 :按方案 (PP)分析分别为 87.0 %( 4 7/ 5 4)、82 .4%( 4 2 / 5 1)和 80 .8%( 4 2 / 5 2 ) ,按意图治疗 (ITT)分析分别为 85 .5 %( 4 7/ 5 5 )、77.8%( 4 2 / 5 4)和 77.8%( 4 2 / 5 4) ,P均 >0 .0 5。A、B、C 3组的ADR发生率分别为 5 .5 6 %( 3/ 5 4)、2
Objective: To observe the efficacy and safety of omeprazole, amoxicillin and furazolidone short-course triple therapy as a second-line regimen for the eradication of Helicobacter pylori (HP). Methods: Thirty-six HP-infected patients who had undergone a triple-therapy with proton pump inhibitor-based eradication or relapse after eradication were randomized into groups A, B and C, group A (n = 55, male 42, female 13, age 63 ± 13 years) were given omeprazole (O) 200mg, amoxicillin (A) 100mg, furazolidone (F) 10mg, bid, treatment 7d (referred to as OAF program); B group n = 5 4, males 44, females 10, and age 6 1 ± 13 years) were given omeprazole 20 mg, de novo (C) 2 40 mg, metronidazole 40 mg, bid, tetracycline (N = 54 male 43, female 11, age 6 2 ± 17) were given omeprazole 20 mg, Deno 2 40 mg, metronidazole 40 0 mg , Amoxicillin 10 0mg, bid, treatment 7d (referred to as OCMA program). Anti-HP treatment after the end of January, all done 13 C urea breath test. Results: There were 1 case lost in each group, 2 cases in group B due to adverse drug reaction (ADR) and 1 case in group C due to ADR. The HP eradication rates in groups A, B and C were 87.0% (47/54), 82.4% (4 2/5 1) and 80.8% (4 2 / (ITT) were 85.5% (77/45), 77.8% (4 2/544) and 77.8% (42/54) respectively, all P> 0. 0 5. The incidences of ADR in groups A, B and C were respectively 5.56% (3/5 4), 2